Medical Therapy for Hypertension

Medical Therapy for Hypertension

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history, genetic factors, and concurrent conditions. Always consult qualified healthcare providers for medical decisions and before making changes to your care. Never delay seeking medical care based on content you have read. If you are experiencing a medical emergency, seek immediate medical attention.

This article is education to help you partner with your clinicians; it is not a substitute for individualized medical advice. All treatment decisions should involve your healthcare team.

---

In Brief

Lowering systolic blood pressure by 10 mmHg cuts the risk of major cardiovascular events by about 20%, coronary disease by 17%, stroke by 27%, heart failure by 28%, and all-cause mortality by 13%. (11) That is what blood pressure medication is for.

Each major drug class works on a different part of the system that drives blood pressure up: vascular tone, kidney sodium handling, the renin-angiotensin-aldosterone system (RAAS), or sympathetic signaling. Most adults with hypertension have more than one of these systems involved, which is why most adults end up on more than one medication — and why two medications at moderate doses usually work better, and feel better, than one medication at maximum dose. (1,10)

The point is not the number on the cuff. The point is fewer heart attacks, fewer strokes, less heart failure, and a longer life. Knowing what each medication is doing — and why — is how you and your clinician build a regimen you can actually live with.

Scope note: This article applies to adults with primary (essential) hypertension. Pregnancy, advanced kidney disease, severe heart failure, and secondary causes require condition-specific management beyond the scope of this article.

---

Medications Target Physiology, Not Just Numbers

Different blood pressure medications work in different ways. Knowing what each one does explains why the regimen looks the way it does. (1)

Blood pressure is the product of how hard the heart pumps and how much resistance the vessels offer. Long-term, it is shaped by how the kidneys handle sodium and water and by two signaling systems — the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. (1–3) The major drug classes each target one of those levers:

• Calcium channel blockers (CCBs) relax vascular smooth muscle, lowering the resistance arteries place on flow. (1)
• Thiazide-type diuretics act on kidney sodium handling, with additional vascular effects that develop over weeks and account for much of their sustained benefit. (1,4)
• ACE inhibitors and ARBs block angiotensin II, reducing both vasoconstriction and sodium retention. (5,6)
• Beta blockers reduce adrenergic signaling, lowering heart rate, cardiac contractility, and renin release. (1,7–9)

As Article 3 covered, hypertension is usually multiple physiologic systems pushing in the same direction at once. Two patients with identical readings can respond very differently to the same drug because the dominant biology differs. Matching the drug to the dominant mechanism — and to any coexisting cardiovascular or kidney conditions — is the core of how regimens are built. (1,10)

That is also why more than one drug is usually needed. (1,10)

---

Why Medications Are Commonly Required

Lifestyle changes lower blood pressure (Article 6 covered the evidence), but for many people they are not enough on their own. Each 10 mmHg drop in systolic blood pressure reduces major cardiovascular events by about 20%. (11) When lifestyle gets you partway there and medication gets you the rest of the way, the benefit is real.

Some people need medication despite excellent habits. Genetics, aging arteries, kidney biology, or other contributors can keep pressure high regardless of effort. Medication is often part of the regimen for biological reasons.

Needing more than one medication is also common. Most people with hypertension eventually take two or more, because more than one biological system is usually involved. The 2025 AHA/ACC guideline explicitly recommends starting Stage 2 hypertension (≥140/90 mmHg) with a single-pill, two-drug combination rather than waiting for one drug to prove insufficient. (1)

Population data show that a large share of treated adults still do not have their blood pressure controlled. (12) That gap is rarely solved by stronger drugs alone — it usually involves measurement quality, follow-up, adherence, and identifying substances that work against treatment.

Healthcare-system realities also shape what regimens look like in practice. Short visit times, fragmented care across specialties, medication costs, insurance formularies that favor some drugs over others, and limited follow-up after a prescription is written all affect whether a regimen actually works. None of this is reflected in the trial data, but all of it influences whether a patient is still controlled a year later. The best regimen on paper is not the same as the best regimen in real life.

---

Risk Reduction Is the Goal, Not “Perfect Numbers”

The number on the cuff is a tool. The goal is fewer heart attacks, fewer strokes, less heart failure, and a longer life. (1,11)

For most adults with hypertension, the 2025 AHA/ACC guideline recommends a treatment target of <130/80 mmHg, with more intensive targets (such as <120 mmHg systolic) reasonable in selected patients who tolerate them well. Older or frail adults often warrant individualized targets to avoid orthostatic hypotension and falls. (1)

Cardiovascular risk reflects years of cumulative pressure on the arteries, not a single reading. (11) A high reading on a stressful afternoon does not undo months of good control, and a low reading on a relaxed morning does not undo months of elevated pressure.

The best regimen is the one you can actually take. A regimen that produces beautiful numbers but gets abandoned because of side effects has lowered no one’s risk.

---

First-Line Foundations in Adult Primary Hypertension

The 2025 AHA/ACC hypertension guideline identifies three foundational first-line medication families for most adults with primary hypertension without compelling indications for another class: (1)

• Thiazide or thiazide-like diuretics
• Dihydropyridine calcium channel blockers
• ACE inhibitors or ARBs

These classes became foundational because they consistently improved cardiovascular outcomes across broad hypertensive populations in randomized trials, not simply because they lower blood pressure. (1,13–15)

The 2025 guideline reserves beta blockers for compelling indications — post–myocardial infarction, heart failure with reduced ejection fraction, angina, certain arrhythmias, or rate control — rather than routine first-line use for uncomplicated hypertension. (1,7,8)

---

How the Core Drug Classes Work

ACE Inhibitors and ARBs

Mechanism. ACE inhibitors reduce angiotensin II formation; ARBs block angiotensin II receptor signaling. Angiotensin II contributes to vasoconstriction, sodium retention, and aldosterone release, so RAAS blockade lowers blood pressure through coupled vascular and renal mechanisms. (5,6)

Comparative effectiveness. ACE inhibitors and ARBs produce similar blood pressure reductions in head-to-head comparisons. (16) The major distinction between the classes is the side-effect profile, particularly the substantially lower rate of cough with ARBs.

Cough and angioedema. ACE inhibitor cough is thought to relate partly to bradykinin accumulation in the airways, since ACE normally degrades bradykinin in addition to converting angiotensin I to angiotensin II. (17) Angioedema is a less common but more serious side effect tied to similar pathways. ARBs do not affect bradykinin and have substantially lower rates of both. (16,17)

Why RAAS blockade matters beyond the cuff. RAAS blockade is especially important when hypertension overlaps with diabetes, chronic kidney disease, heart failure, or proteinuric kidney disease. (1,18,19) HOPE showed event reduction with ramipril in high-risk patients including those with diabetes and vascular disease; RENAAL showed losartan slowed progression to end-stage renal disease in patients with type 2 diabetes and overt nephropathy. (18,19)

Combination caution. Guidelines discourage routine dual RAAS blockade (an ACE inhibitor plus an ARB, or either plus a direct renin inhibitor) because of safety concerns including hypotension, kidney injury, and hyperkalemia. (1)

Calcium Channel Blockers

Mechanism. Reduced calcium entry into vascular smooth muscle leads to vasodilation and reduced systemic vascular resistance. (1) Dihydropyridine CCBs (such as amlodipine) primarily affect vascular smooth muscle rather than heart rate or cardiac conduction; non-dihydropyridine CCBs (verapamil, diltiazem) affect both and are used in different contexts.

Outcomes. Large trials support CCB-based strategies as broadly comparable to other first-line strategies for major cardiovascular outcomes across hypertensive populations. (13,14)

Edema. Peripheral edema is consistently associated with CCBs and is one of the most common reasons patients discontinue them. (20) The edema reflects altered vascular fluid dynamics — preferential arteriolar dilation that shifts fluid into tissues — rather than simple sodium or volume overload. This is why standard diuretics often do not relieve CCB edema well, and why dose reduction or class change is usually a better approach.

Thiazide and Thiazide-Like Diuretics

Mechanism. Thiazides act on renal sodium handling at the distal convoluted tubule. The long-term blood pressure effects extend beyond simply “making people urinate more”; vascular and neurohormonal effects emerge over weeks and account for much of the sustained reduction. (4) Patients can benefit from thiazide therapy even without obvious swelling or fluid retention.

Outcomes. ALLHAT compared chlorthalidone with ACE inhibitor and CCB strategies in high-risk hypertensive patients and supported diuretic-based therapy as comparable on outcomes. (13) SHEP demonstrated stroke reduction in older adults with isolated systolic hypertension treated with a diuretic-based regimen. (15)

Monitoring. Electrolyte disturbances — particularly low potassium and low sodium — and kidney function changes are central to how thiazide therapy is monitored and adjusted. (1,4)

---

Where Beta Blockers Fit

Patients encounter beta blockers frequently, and they improve outcomes in specific cardiovascular contexts. The key is correct positioning.

Mechanism. Beta blockers reduce adrenergic signaling, lowering heart rate, cardiac contractility, and renin release. (9)

Guideline positioning. Contemporary hypertension guidelines, including the 2025 AHA/ACC update, do not place beta blockers as default first-line therapy for uncomplicated primary hypertension. They become central when hypertension overlaps with conditions where beta blockers improve outcomes — heart failure with reduced ejection fraction, post–myocardial infarction populations, angina, or when there is a coexisting need for heart rate control (such as atrial fibrillation). (1,7,8)

Outcome evidence. MERIT-HF supported metoprolol succinate in chronic heart failure with reduced ejection fraction; CAPRICORN supported carvedilol after myocardial infarction with left ventricular dysfunction. (7,8)

Not all beta blockers are interchangeable. Carvedilol, metoprolol succinate, and bisoprolol have specific evidence in heart failure; not every beta blocker has been shown to produce the same benefit.

Discontinuation. Some beta blockers should not be stopped abruptly without clinician guidance, because withdrawal can produce clinically important rebound effects — increased heart rate, increased blood pressure, and in patients with coronary disease, increased angina risk. (1,9)

---

Why Two Drugs Usually Beat One

When one medication does not bring blood pressure to target, adding a second drug from a different class almost always works better than pushing the first drug to higher doses. A meta-analysis of 42 factorial trials in 11,000 participants found that adding a second drug class produced about five times the additional blood pressure reduction that doubling the first drug’s dose would. (10) Most side effects are dose-related, so two drugs at moderate doses usually produce more reduction with fewer side effects than one drug at maximum dose.

The biology supports this. Blocking one pathway often triggers compensation elsewhere — diuretics can activate RAAS; RAAS blockade can prompt sodium retention. Combining classes that cover each other’s compensatory responses produces more durable control than maximizing any single mechanism. (1,10)

Combination selection can matter for outcomes. In ACCOMPLISH, an ACE inhibitor plus CCB strategy reduced cardiovascular events more than an ACE inhibitor plus thiazide strategy in a high-risk hypertensive cohort. (21) This does not make one combination universal, but it shows the choice is not arbitrary.

The 2025 AHA/ACC guideline favors single-pill combinations for Stage 2 hypertension to simplify regimens and improve adherence. (1)

---

Resistant Hypertension and the Role of Aldosterone

When blood pressure remains above target despite three or more antihypertensive drug classes at maximum or maximally tolerated doses (typically including a diuretic, an ACE inhibitor or ARB, and a calcium channel blocker), clinicians work through a structured evaluation rather than simply adding more drugs. The AHA resistant hypertension framework emphasizes confirming the blood pressure signal, assessing adherence, identifying interfering agents, evaluating for secondary causes, and optimizing the regimen. (22)

Apparent resistant hypertension is not always true biologic resistance. Common causes of apparently resistant readings include inaccurate measurement, nonadherence, high sodium intake or alcohol use, interfering medications, and white-coat effect. Sorting these out before escalating medications is part of why resistant hypertension is framed as an evaluation problem first.

Aldosterone is increasingly recognized as a major contributor. Modern resistant hypertension research increasingly identifies aldosterone biology as a driver of persistent sodium-retentive hypertension, even when frank primary aldosteronism is not diagnosed. (22) PATHWAY-2 provided randomized evidence that spironolactone is more effective than bisoprolol or doxazosin as an add-on therapy for resistant hypertension in patients already on a three-drug regimen. (23) Because mineralocorticoid receptor antagonists (MRAs) interact directly with kidney potassium handling, laboratory monitoring of potassium and creatinine is central to safe use. (22–24)

---

Other Medication Classes Patients Commonly Encounter

Mineralocorticoid Receptor Antagonists (MRAs). Spironolactone and eplerenone are used as add-ons in resistant hypertension, supported by the AHA resistant hypertension framework and PATHWAY-2. Hyperkalemia risk is clinically meaningful, particularly in chronic kidney disease or when combined with RAAS blockade. (22–24)

Alpha-1 Blockers. Doxazosin and similar agents may appear as add-ons or in selected contexts (such as concurrent benign prostatic hyperplasia). ALLHAT’s doxazosin arm was stopped early because the doxazosin group had higher rates of heart failure and combined cardiovascular events than the chlorthalidone group, which decreased enthusiasm for alpha-1 blockers as routine hypertension therapy. (25)

Central Alpha-Agonists. Clonidine and similar agents are later-line options under clinician supervision. Withdrawal-associated rebound hypertension is a major practical limitation; abruptly stopping clonidine can produce dangerous blood pressure spikes. (26)

Direct Vasodilators. Hydralazine and minoxidil are used in severe or resistant contexts under specialist care. Reflex tachycardia and fluid retention typically require accompanying beta blocker and diuretic therapy, limiting routine use. Hydralazine can also cause a drug-induced lupus-like syndrome. (27,28)

Direct Renin Inhibitors. Aliskiren is uncommon in modern practice. The ALTITUDE trial raised safety concerns when aliskiren was added to ACE inhibitor or ARB therapy in high-risk type 2 diabetes populations, shaping caution about dual RAAS-blocking combinations. (29)

SGLT2 Inhibitors

SGLT2 inhibitors were developed as glucose-lowering agents but have emerged as important cardiorenal therapies with modest antihypertensive effects. (30) The blood pressure reduction is typically ~2–4 mmHg systolic — less than dedicated antihypertensives — but the mechanism is distinct: SGLT2 inhibitors promote natriuresis and osmotic diuresis without activating the compensatory neurohormonal systems that traditional diuretics can. (30)

Cardiovascular outcomes trials demonstrated reductions in heart failure hospitalization and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58). (31–33) Subsequent trials extended benefit to heart failure with reduced ejection fraction regardless of diabetes status (DAPA-HF, EMPEROR-Reduced) and to chronic kidney disease (DAPA-CKD). (34–36)

The blood pressure effect alone does not explain the magnitude of cardiovascular and renal benefit observed in these trials. When hypertension coexists with type 2 diabetes, heart failure, or CKD, SGLT2 inhibitors are increasingly used not primarily for blood pressure but because the cardiorenal outcome benefits extend well beyond glycemic or hemodynamic effects. Class-specific adverse effects include genital mycotic infections, euglycemic diabetic ketoacidosis (rare), and volume depletion in susceptible patients. (30–33)

---

Many Blood Pressure Drugs Have Non–Blood Pressure Roles

Some antihypertensive medications are chosen because they also improve outcomes in coexisting cardiovascular or kidney conditions. Guidelines call these “compelling indications” — a coexisting condition that makes a particular class the preferred choice regardless of where it would otherwise rank. (1)

• ACE inhibitors and ARBs are preferred in diabetes with albuminuria, chronic kidney disease, heart failure with reduced ejection fraction, and post–myocardial infarction with left ventricular dysfunction. (1,18,19)
• Beta blockers (specific agents) improve outcomes in HFrEF, post-MI, angina, and certain arrhythmias. (1,7,8)
• MRAs improve outcomes in HFrEF and resistant hypertension. (22,23)
• SGLT2 inhibitors reduce cardiovascular and renal events in diabetes, heart failure (regardless of diabetes status), and CKD. (30–36)
• Thiazide-like diuretics have specific stroke-reduction evidence in isolated systolic hypertension. (15)

Two patients with the same blood pressure may end up on different medications because the rest of their cardiovascular picture is different.

---

Side Effects Are Often Mechanism-Related

Most side effects of blood pressure medications are predictable from the way the drug works. Knowing which class causes which effect is how clinicians fix problems without abandoning treatment — usually with a dose change, a timing change, or a switch to a different drug in the same class.

Class	Common safety themes	Evidence
ACE inhibitors	Cough; angioedema; kidney function and potassium monitoring	(1,17,24)
ARBs	Similar efficacy to ACE inhibitors with lower cough risk; kidney and potassium monitoring	(1,16,24)
Calcium channel blockers	Peripheral edema (vascular, not volume); reflex effects	(20)
Thiazide-type diuretics	Low potassium and sodium; uric acid; glucose effects	(1,4)
Beta blockers	Bradycardia; fatigue; avoid abrupt discontinuation in some contexts	(1,9)
MRAs	Hyperkalemia (especially with RAAS blockade or CKD)	(22–24)
Alpha-1 blockers	Orthostatic hypotension; ALLHAT outcomes context	(25)
Central alpha-agonists	Rebound hypertension on abrupt withdrawal	(26)
Direct vasodilators	Reflex tachycardia, fluid retention, drug-induced lupus (hydralazine)	(27,28)
SGLT2 inhibitors	Genital mycotic infections; euglycemic DKA (rare); volume depletion	(30–33)

---

Interference: A Common Reason Control Fails

A lot of apparent medication “failure” is actually pressure being pushed up by something else. Resistant hypertension frameworks specifically emphasize identifying these substances before escalating drugs. (22)

Exposure	What the literature shows	Evidence
NSAIDs (ibuprofen, naproxen)	Average ~5 mmHg systolic rise; renal risk when combined with ACE inhibitor/ARB plus diuretic (“triple whammy”)	(37,38)
Pseudoephedrine and similar decongestants	Small average blood pressure and heart rate increase; greater effects with higher doses, immediate-release preparations, and in some individuals	(39)
True licorice (Glycyrrhiza glabra)	Dose-dependent blood pressure elevation	(40)

Over-the-counter supplements, stimulants, and performance-enhancing products can also interfere with blood pressure control. Pre-workout supplements heavy in stimulants, certain weight-loss products, high-dose energy drinks, and anabolic compounds all can raise blood pressure or blunt medication effects. So can recreational stimulants. Sharing a complete list of everything taken — including supplements and over-the-counter products — is part of what makes regimen optimization possible.

---

Monitoring: What It Is For

Blood pressure medications affect more than the cuff reading — they alter kidney function, electrolytes, vascular tone, and hormonal systems. Monitoring exists to catch those changes early. (1,22)

Guidelines and resistant hypertension frameworks recommend monitoring tailored to the regimen: (1,22–24)

• RAAS-blocking drugs (ACE inhibitors, ARBs, MRAs) → potassium and creatinine
• Diuretics (thiazide-type, MRAs) → potassium, sodium, kidney function
• All regimens → measurement quality at home and in clinic, periodic reassessment as risk factors and conditions change

Monitoring is not bureaucracy. It is how clinicians catch problems early enough to adjust the regimen rather than encounter them as complications.

---

Special Situations Where Safety Rules Change

Pregnancy. ACE inhibitors, ARBs, direct renin inhibitors, and MRAs are contraindicated in pregnancy because of fetal harm; first-trimester ACE inhibitor exposure is associated with increased risk of major congenital malformations. (41,42) Pregnancy-specific management uses agents with established safety records.

Chronic kidney disease. Blood pressure therapy selection and monitoring are individualized; KDIGO provides a structured framework for blood pressure management in CKD, and RAAS blockade is generally preferred when albuminuria is present. (43)

Older adults. Older patients are more likely to develop orthostatic hypotension and to fall, which influences both the pace of medication titration and target selection. The 2025 AHA/ACC guideline emphasizes individualized targets in frail or older populations. (1)

---

Questions Worth Discussing With Your Care Team

Understanding the reasoning behind your blood pressure regimen helps you participate more effectively in your own care. Consider asking:

• What physiology is each of my medications targeting, and why was this combination chosen for me? (1)
• What blood pressure target are we aiming for, and how are we confirming the readings are accurate? (1,22)
• What monitoring do I need on this regimen, and how often? (1,22–24)
• Are any of my medications, supplements, or over-the-counter products potentially interfering with control? (22,37–40)
• If I notice a side effect, how do we identify which medication is most likely responsible and what alternatives exist? (1,16,17,20,22,23)
• If my blood pressure improves substantially over time with lifestyle changes, how would we approach any medication changes safely?

---

What This Means

Blood pressure medications save lives. The evidence is not subtle. A sustained 10 mmHg drop in systolic pressure reduces major cardiovascular events by 20%, stroke by 27%, and heart failure by 28%. (11) Treating hypertension is one of the most powerful interventions in medicine.

The medications that earned first-line status — thiazide-type diuretics, dihydropyridine calcium channel blockers, and ACE inhibitors or ARBs — earned it the hard way, in randomized trials measuring heart attacks, strokes, and deaths. (1,13–15) Beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors earn their place when specific conditions make them the right choice. None of this is arbitrary.

Three things to take away:

1. Most people need more than one medication. That is normal. Combining lower doses of two complementary drugs almost always works better — and is better tolerated — than pushing a single drug to its maximum. (10)
2. Side effects usually have a fix. Most are predictable from the mechanism. Dose adjustment, timing changes, or switching to a different agent in the same class often resolves them without abandoning treatment. (1,20)
3. What you take outside the prescription matters. NSAIDs, decongestants, true licorice, high-sodium intake, heavy alcohol, and stimulant-heavy supplements can quietly raise pressure and make treatment look like it is failing. (22,37–40) Tell your clinician everything you take.

You are not chasing a number on a cuff. You are protecting your brain, your heart, your kidneys, and your years. Article 8 covers environmental and emerging risk factors that influence hypertension beyond the major lifestyle and medication levers we have covered so far.

---

Key Terms

RAAS: Renin-angiotensin-aldosterone system. A coordinated hormonal cascade that regulates blood pressure, sodium balance, and fluid volume. Many blood pressure medications act on this system.

ACE inhibitor / ARB: Two classes of RAAS-blocking medications. ACE inhibitors reduce production of angiotensin II; ARBs block its receptor. Similar blood pressure efficacy, different side-effect profiles.

Calcium channel blocker (CCB): A medication class that relaxes vascular smooth muscle by reducing calcium entry. Dihydropyridine CCBs (amlodipine, nifedipine) primarily act on vessels; non-dihydropyridine CCBs (verapamil, diltiazem) also affect heart rate.

Thiazide-type diuretic: A medication class that acts on the kidney to influence sodium handling and has additional vascular effects over time. Used as a first-line antihypertensive and as a partner in combination therapy.

Beta blocker: A medication class that reduces adrenergic signaling. Not a default first-line choice for uncomplicated hypertension under current guidelines, but a core therapy when heart failure, post-MI, angina, or rate control are present.

Mineralocorticoid receptor antagonist (MRA): A medication class (spironolactone, eplerenone) that blocks aldosterone’s effects on the kidney. Useful in resistant hypertension and heart failure; requires potassium monitoring.

Resistant hypertension: Blood pressure above target despite concurrent use of three antihypertensive drug classes at maximum or maximally tolerated doses (typically including a diuretic, an ACE inhibitor or ARB, and a calcium channel blocker), or controlled blood pressure requiring four or more medications. A structured evaluation problem more than a pharmacology problem.

Compelling indication: A coexisting condition where a particular medication class has specific outcomes evidence and becomes the preferred choice regardless of where it would otherwise rank in first-line algorithms.

Cumulative blood pressure exposure: The total burden of elevated pressure on the cardiovascular system over years. Long-term cardiovascular risk reflects this cumulative exposure rather than any single reading.

---

References

1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension.2025;82(10):e212–e316. (Co-published in J Am Coll Cardiol 2025;86(18):1567–1678 and Circulation2025;152:e114–e218.)
2. Guyton AC. Blood pressure control—special role of the kidneys and body fluids. Science. 1991;252(5014):1813–1816.
3. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3):625–633.
4. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793–802.
5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–1420.
6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637–645.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
8. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–1390.
9. Frishman WH, Saunders E. β-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13(9):649–653.
10. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.
11. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
12. Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324(12):1190–1200.
13. ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
14. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031.
15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265(24):3255–3264.
16. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16–29.
17. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–242.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861–869.
20. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate—a meta-analysis of randomized trials. J Hypertens.2011;29(7):1270–1280.
21. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH). N Engl J Med. 2008;359(23):2417–2428.
22. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–e90.
23. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068.
24. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58(5):2084–2092.
25. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000;283(15):1967–1975.
26. Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal: mechanism and frequency of rebound hypertension. Br J Clin Pharmacol. 1979;7(1):55–62.
27. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep.2002;4(6):479–482.
28. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed). 1984;289(6442):410–412.
29. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes (ALTITUDE). N Engl J Med. 2012;367(23):2204–2213.
30. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet.2019;393(10166):31–39.
31. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
32. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS Program). N Engl J Med. 2017;377(7):644–657.
33. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58). N Engl J Med. 2019;380(4):347–357.
34. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008.
35. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413–1424.
36. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446.
37. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289–300.
38. Loboz KK, Shenfield GM. Drug combinations and impaired renal function—the “triple whammy”. Br J Clin Pharmacol. 2005;59(2):239–243.
39. Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005;165(15):1686–1694.
40. Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S. Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens. 2001;15(8):549–552.
41. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–2451.
42. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26–e50.
43. Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1–S87.